<?xml version="1.0" encoding="UTF-8"?>
<p>Remdesivir (8), a nucleotide analog pro-drug developed by Gilead Sciences Inc. to fight Ebola, acts on viral replication by inhibiting RNA polymerase.
 <xref rid="B96" ref-type="bibr">
  <sup>96</sup>
 </xref> This molecule was also active against SARS and MERS viruses.
 <xref rid="B200" ref-type="bibr">
  <sup>200</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B201" ref-type="bibr">
  <sup>201</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B202" ref-type="bibr">
  <sup>202</sup>
 </xref> Wang et al. demonstrated reduced viral copy numbers in cell culture supernatant of Vero E6 cells infected with nCoV- 2019BetaCoV/Wuhan/WIV04/20192, in the presence of varying concentrations of Remdesivir (8).
 <xref rid="B194" ref-type="bibr">
  <sup>194</sup>
 </xref> This compound blocked virus infection at low-micromolar concentration (EC
 <sub>50</sub> = 0.77 Î¼M) and showed a high selectivity index (&gt; 100). The authors also disclosed that remdesivir (8) inhibited virus infection efficiently in human liver cancer Huh-7 cells.
</p>
